Financials

v3.6.0.2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
Current Assets    
Cash and cash equivalents $ 19,055 $ 20,818
Prepaid expenses and other current assets 2,515 9,519
Total Current Assets 21,570 30,337
Property and equipment, net 905 494
Deposits and other assets 23 14
Total Assets 22,498 30,845
Current Liabilities:    
Accounts payable 1,993 4,413
Accrued expenses 2,627 297
Warrant liabilities 14,821 10,567
Accrued employee benefits 313 277
Deferred rent 3 21
Total Current Liabilities 19,757 15,575
Long term deferred rent 492 267
Total Liabilities 20,249 15,842
Commitments and Contingencies 0 0
Stockholders' Equity:    
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding 0 0
Common stock, $0.001 par value; 250,000,000 shares authorized, 117,254,196 issued and 117,172,714 outstanding and 90,908,234 issued and 90,826,752 outstanding, respectively 117 91
Additional paid-in capital 175,762 160,739
Accumulated deficit (172,034) (144,779)
Total Synthetic Biologics, Inc. and Subsidiaries Equity 3,845 16,051
Non-controlling interest (1,596) (1,048)
Total Stockholders' Equity 2,249 15,003
Total Liabilities and Stockholders' Equity $ 22,498 $ 30,845

Source

v3.6.0.2
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Operating Costs and Expenses:      
General and administrative $ 10,143 $ 8,074 $ 6,013
Research and development 29,109 32,906 14,489
Total Operating Costs and Expenses 39,252 40,980 20,502
Loss from Operations (39,252) (40,980) (20,502)
Other Income (Expense):      
Change in fair value of warrant liability 11,412 (3,811) 620
Other income 0 0 95
Interest income 37 6 3
Total Other Income (Expense) 11,449 (3,805) 718
Net Loss (27,803) (44,785) (19,784)
Net Loss Attributable to Non-controlling Interest (548) (1,048) 0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries $ (27,255) $ (43,737) $ (19,784)
Loss Per Share - Basic and Dilutive $ (0.29) $ (0.54) $ (0.32)
Net Income (Loss) Per Share - Basic and Dilutive      
Weighted average number of shares outstanding during the period - Basic and Dilutive 94,290,436 80,705,692 61,945,356

Source

v3.6.0.2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Cash Flows From Operating Activities:      
Net Loss $ (27,803) $ (44,785) $ (19,784)
Adjustments to reconcile net loss to net cash used in operating activities:      
Stock-based compensation 4,009 3,198 2,459
Stock issued for milestone payments 0 1,350 0
Stock issued for exclusive channel collaboration agreement 0 3,000 0
Change in fair value of warrant liabilities (11,412) 3,811 (620)
Depreciation 157 72 20
Changes in operating assets and liabilities:      
Prepaid expenses and other current assets 7,004 (7,971) 43
Deposits and other assets (9) (8) (2)
Accounts payable (2,420) 3,417 854
Accrued expenses 2,330 (1,001) 416
Accrued employee benefits 36 (261) 535
Deferred rent 207 288 0
Net Cash Used In Operating Activities (27,901) (38,890) (16,079)
Cash Flows From Investing Activities:      
Purchases of property and equipment (569) (501) (48)
Net Cash Used In Investing Activities (569) (501) (48)
Cash Flows From Financing Activities:      
Proceeds from issuance of common stock 25,000 46,000 20,668
Cash paid as direct offering costs (616) (3,357) (1,645)
Proceeds from issuance of common stock for stock option exercises 814 41 4
Proceeds from "at the market" stock issuance 1,509 0 0
Net Cash Provided By Financing Activities 26,707 42,684 19,027
Net (decrease) increase in cash (1,763) 3,293 2,900
Cash at beginning of period 20,818 17,525 14,625
Cash at end of period 19,055 20,818 17,525
Supplemental disclosures of cash flow information:      
Cash paid for interest 0 0 0
Cash paid for taxes $ 0 $ 0 $ 0

Source